Published in Cancer Lett on February 10, 2004
SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. PLoS One (2012) 1.01
PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res (2012) 1.00
Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. Oncogene (2011) 0.96
Neuronal differentiation of synovial sarcoma and its therapeutic application. Clin Orthop Relat Res (2008) 0.95
Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One (2012) 0.95
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer (2014) 0.89
β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition. Oncotarget (2015) 0.87
Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants. Virchows Arch (2006) 0.87
The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). PLoS One (2013) 0.86
Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther (2008) 0.82
SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene (2012) 0.79
Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma (2009) 0.79
Modeling synovial sarcoma metastasis in the mouse: PI3'-lipid signaling and inflammation. J Exp Med (2016) 0.78
Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. Sci Rep (2016) 0.78
SYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 protein. J Biol Chem (2011) 0.77
Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth. Clin Orthop Relat Res (2008) 0.77
Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma. Cancer Sci (2016) 0.77
Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2'-deoxycytidine against synovial sarcoma cell lines. J Cancer Res Clin Oncol (2010) 0.77
Effect of temozolomide on the viability of musculoskeletal sarcoma cells. Oncol Lett (2015) 0.76
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas. BMC Cancer (2016) 0.75
Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells. Sci Rep (2017) 0.75
Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells. Mol Med Rep (2016) 0.75
Explant culture of sarcoma patients' tissue. Lab Invest (2016) 0.75
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma. PLoS One (2017) 0.75
Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein. PLoS One (2013) 0.75
Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma. BMC Cancer (2017) 0.75
Characterization of a novel radiation-induced sarcoma cell line. J Surg Oncol (2015) 0.75
Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors. Oncol Lett (2017) 0.75
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res (2006) 1.91
Accurate diagnosis of musculoskeletal lesions by core needle biopsy. J Surg Oncol (2006) 1.83
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum (2004) 1.67
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res (2002) 1.48
Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer (2005) 1.45
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res (2004) 1.39
Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy. Biochem Biophys Res Commun (2002) 1.37
Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene (2002) 1.34
Primary dedifferentiated liposarcoma of the retroperitoneum. Prognostic significance of computed tomography and magnetic resonance imaging features. J Comput Assist Tomogr (2003) 1.32
Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer (2007) 1.32
Synovial sarcoma of the soft tissues: prognostic significance of imaging features. J Comput Assist Tomogr (2004) 1.31
Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol (2007) 1.31
Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol (2010) 1.30
Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther (2011) 1.29
Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer (2003) 1.23
Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci (2009) 1.22
Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci (2008) 1.19
Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene (2002) 1.19
Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene (2005) 1.18
E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology (2006) 1.13
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer (2007) 1.09
Drug-induced linear IgA bullous dermatosis. J Dermatol (2005) 1.07
Sclerosing perineurioma: a clinicopathological study of five cases and diagnostic utility of immunohistochemical staining for GLUT1. Virchows Arch (2003) 1.07
Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol (2009) 1.06
Bizarre parosteal osteochondromatous proliferation with a t(1;17) translocation. Virchows Arch (2005) 1.05
Clinical evaluation of perceptibility of color differences between natural teeth and all-ceramic crowns. J Dent (2009) 1.04
Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci (2007) 1.04
CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci (2004) 1.03
Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma. Int J Cancer (2010) 1.02
Laparoscopic-assisted resection of gastrointestinal stromal tumor in small intestine. Hepatogastroenterology (2008) 1.02
Downregulation of TESTIN and its association with cancer history and a tendency toward poor survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2009) 1.02
Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature. Sarcoma (2012) 1.01
Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep (2003) 1.01
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett (2004) 1.01
Postoperative deep infection in tumor endoprosthesis reconstruction around the knee. J Orthop Sci (2010) 1.01
Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res (2008) 1.00
Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest (2003) 1.00
Iridium-192 brachytherapy for hemorrhagic angiosarcoma of the scalp: a case report. Jpn J Clin Oncol (2003) 1.00
Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. Int J Oncol (2004) 1.00
Fine deletion mapping of chromosome 2q21-37 shows three preferentially deleted regions in oral cancer. Oral Oncol (2006) 1.00
Bilateral adrenal gland metastasis from malignant fibrous histiocytoma: value of [F-18]FDG PET-CT for diagnosis of occult metastases. Ann Nucl Med (2006) 0.99
Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int J Oncol (2005) 0.99
Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up. Arch Orthop Trauma Surg (2012) 0.98
Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol (2009) 0.98
Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin Cancer Res (2005) 0.97
PuraMatrix facilitates bone regeneration in bone defects of calvaria in mice. Cell Transplant (2006) 0.97
Decreased expression of the SIN3A gene, a candidate tumor suppressor located at the prevalent allelic loss region 15q23 in non-small cell lung cancer. Lung Cancer (2007) 0.97
Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest (2003) 0.97
Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med (2006) 0.97
Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci (2008) 0.96
Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One (2012) 0.95
Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep (2004) 0.95
Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem Biophys Res Commun (2005) 0.95
Pelvic ring reconstruction with the double-barreled vascularized fibular free flap. Plast Reconstr Surg (2005) 0.94
Solitary intramuscular myxoma with monostotic fibrous dysplasia as a rare variant of Mazabraud's syndrome. Skeletal Radiol (2006) 0.94
Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol (2006) 0.94
Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma. Clin Exp Metastasis (2002) 0.94
Use of vascularized free fibular head grafts for upper limb oncologic reconstruction. Plast Reconstr Surg (2011) 0.93
Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats. Int J Pharm (2003) 0.93
Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci (2007) 0.93
Is phenotype difference in severe myoclonic epilepsy in infancy related to SCN1A mutations? Brain Dev (2003) 0.93
Identification of direct targets for the miR-17-92 cluster by proteomic analysis. Proteomics (2011) 0.93
A novel dominant-negative mutation in Gdf5 generated by ENU mutagenesis impairs joint formation and causes osteoarthritis in mice. Hum Mol Genet (2007) 0.92
Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. Cancer Lett (2005) 0.92
SYT-SSX fusion genes in synovial sarcoma of the thorax. Lung Cancer (2004) 0.92
Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther (2013) 0.91
Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics (2011) 0.91
Association of a missense single nucleotide polymorphism, Cys1367Arg of the WRN gene, with the risk of bone and soft tissue sarcomas in Japan. Cancer Sci (2008) 0.91
Extended total sacrectomy and reconstruction for sacral tumor. Spine (Phila Pa 1976) (2004) 0.91
SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. Lab Invest (2004) 0.90